Pelthos director buys 35,948 PTHS shares
Pelthos Therapeutics director Todd C. Davis reported open-market purchases of Pelthos common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Pelthos Therapeutics director Todd C. Davis reported open-market purchases of Pelthos common stock. On June 11, 2026, he bought a total of 35,948 shares in two transactions, at weighted average prices of $27.8046 and $28.7261 per share. Following these trades, his direct holdings increased to 75,834 common shares. The filing also shows 1,500,000 Pelthos shares held indirectly by Ligand Pharmaceuticals Incorporated, where Davis serves as Chief Executive Officer and director; he may be deemed to beneficially own these shares but disclaims beneficial ownership beyond his pecuniary interest.
Insider Trade Summary
Net Buyer: 35,948 shares
Net Buy
3 txns
Insider
Davis Todd C
Role
Director
Bought
35,948 shs ($1000K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 35,445 | $27.8046 | $986K |
| Purchase | Common Stock | 503 | $28.7261 | $14K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 75,834 shares (Direct);
Common Stock — 1,500,000 shares (Indirect, By Ligand Pharmaceuticals Incorporated)
Footnotes (3)
- F1. This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.
Key Figures
Total shares bought: 35,948 shares
Larger trade size: 35,445 shares
Smaller trade size: 503 shares
+4 more
7 metrics
Total shares bought
35,948 shares
Open-market purchases of Pelthos common stock on June 11, 2026
Larger trade size
35,445 shares
Open-market purchase at weighted average price $27.8046
Smaller trade size
503 shares
Open-market purchase at weighted average price $28.7261
Direct holdings after trades
75,834 shares
Pelthos common stock held directly by Todd C. Davis after June 11, 2026
Indirect holdings via Ligand
1,500,000 shares
Pelthos shares held by Ligand Pharmaceuticals Incorporated, attributed indirectly
Weighted average price (large trade)
$27.8046 per share
Multiple trades between $27.63 and $28.49
Weighted average price (small trade)
$28.7261 per share
Multiple trades between $28.72 and $28.94
Key Terms
open-market purchase, weighted average price, beneficially own, pecuniary interest, +1 more
5 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported ... reflects the weighted average price of the shares"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficially own financial
"Mr. Davis may be deemed to beneficially own the shares of Common Stock"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pecuniary interest financial
"disclaims any such beneficial ownership except to the extent of his pecuniary interest"
indirect ownership financial
"total_shares_following_transaction ... ownership_type: indirect"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Pelthos Therapeutics (PTHS) report for Todd C. Davis?
Todd C. Davis reported two open‑market purchases of Pelthos common stock on June 11, 2026. He bought a combined 35,948 shares at weighted average prices around the high‑$20s per share, increasing his direct ownership position in the company.
How were the Pelthos Therapeutics (PTHS) insider trade prices for Todd C. Davis calculated?
Each transaction was executed in multiple trades within a price range, and the reported prices are weighted averages. One set ranged from $27.63 to $28.49, the other from $28.72 to $28.94, with full trade details available on request.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates